½ÃÀ庸°í¼­
»óǰÄÚµå
1675388

Á¤¸Æ³» ¿ä¹ý ¹× Á¤¸Æ ¾×¼¼½º ½ÃÀå : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)

Intravenous Therapy and Vein Access Market by Type, Application, End User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 144 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Á¤¸Æ³» ¿ä¹ý¡¤Á¤¸Æ ¾×¼¼½º ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 263¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ÀÌ ½ÃÀåÀÌ 395¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³âÀÇ ¼ºÀå·ü(CAGR)Àº 4.4%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ ¸¸¿¬, ±³Åë»ç°íÀÇ Áõ°¡, Á¡Àû ¿ä¹ýÀÇ ÀÌÁ¡¿¡ °üÇÑ ¼ÒºñÀÚ ÀǽÄÀÇ Çâ»óÀÌ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù.

Á¤¸Æ³» ¿ä¹ýÀº Á¤¸ÆÀ» ÅëÇØ Ç÷·ù¿¡ Á÷Á¢ ¼öºÐ, ¾à¹°, ¿µ¾çÀ» Åõ¿©ÇÏ´Â ÀÇ·á ½Ã¼úÀÔ´Ï´Ù. ÀÌ ½Ã¼úÀº ´Ù¾çÇÑ Áõ»ó°ú Áúº´À» Ä¡·áÇϱâ À§ÇØ º´¿ø, Áø·á¼Ò, ±âŸ ÀÇ·á ½Ã¼³¿¡¼­ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Á¤¸Æ Á¢±ÙÀº Á¤¸Æ³» Ä¡·á¸¦ À§ÇØ Á¤¸ÆÀ¸·Î µé¾î°¡´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ÀÇ·á Àü¹®°¡´Â ÀϹÝÀûÀ¸·Î ¹Ù´ÃÀ» »ç¿ëÇÏ¿© ÇǺθ¦ ¶Õ°í Á¤¸Æ¿¡ Á¢±ÙÇÏÁö¸¸, Á¤¸ÆÀÌ °¡´Ã°Å³ª ¼Õ»óµÈ Á¤¸Æ, Å»¼ö, ºñ¸¸ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ÀϺΠȯÀÚ¿¡°Ô´Â ¾î·Á¿òÀÌ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ¼ö¾×¿ä¹ý¿¡´Â ¿©·¯ À¯ÇüÀÌ Àִµ¥, Å»¼öÁõ¿¡ ´ëÇÑ ½Ä¿°¼ö, °¨¿°¿¡ ´ëÇÑ Ç×»ýÁ¦, ¾Ï Ä¡·á¿¡ ´ëÇÑ È­Çпä¹ý µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´À» Ä¡·áÇÏ´Â °Í»Ó¸¸ ¾Æ´Ï¶ó ¿¹¹æÁ¢Á¾À̳ª ºñŸ¹Î Åõ¿© µî ¿¹¹æÀû Àǹ̷εµ ¼ö¾×¿ä¹ýÀ» ½ÃÇàÇÏ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.

Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀå µ¿Çâ :

¾Ï, ´ç´¢º´, ÀÚ°¡¸é¿ªÁúȯ µî Àå±âÀûÀÎ Åõ¾à°ú ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ ¸¸¼ºÁúȯ ¹× »ýȰ½À°üº´ÀÇ À¯º´·ü Áõ°¡°¡ Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ±³Åë»ç°í ¹ß»ý·ü Áõ°¡¿Í ¿Ü»ó »ç·ÊÀÇ ±ÞÁõµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±ÙÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í ÁßÁõ ȯÀÚ Ä¡·á Áõ°¡´Â ½ÃÀå¿¡ À¯ÀÍÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ¿Í ÇÔ²² ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ º¯È­Çϰí ÀÖ´Â °Íµµ Áß¿äÇÑ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ½Ã°£°ú ³ë·ÂÀ» ÁÙÀ̰í, °¨¿° À§ÇèÀ» ³·Ã߸ç, ½Ã¼úÀÇ Á¤È®¼ºÀ» Çâ»ó½ÃŰ´Â ÀÇ·á »ê¾÷ÀÇ ¼ö¸¹Àº ±â¼ú ¹ßÀüÀº ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² »õ·Î¿î Ä¡·á¹ý, ¾àǰ, ±â±â Çõ½ÅÀ» À§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ÅõÀÚ°¡ ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·áºñ ÁöÃâ Áõ°¡, º´¿ø ¼ö Áõ°¡, ÀçÅÃÄ¡·áÀÇ º¸±Þ, ³ëÀÎ Àα¸ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • ¼¼°è Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ÃßÀÌÇØ ¿Ô´Â°¡?
  • ¼¼°è Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ ¹× ±âȸ´Â?
  • °¢ ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ°¡ ¼¼°èÀÇ Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ ±¹°¡´Â?
  • À¯Çüº° ½ÃÀå ºÐ¼®Àº?
  • Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ À¯ÇüÀº?
  • ¿ëµµº° ½ÃÀå ºÐ¼®Àº?
  • Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ ¿ëµµ´Â?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº?
  • Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ ÃÖÁ¾»ç¿ëÀÚ´Â?
  • ¼¼°è Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀåÀÇ °æÀï ±¸µµ´Â?
  • ¼¼°èÀÇ Á¤¸Æ³» Ä¡·á ¹× Á¤¸Æ Á¢±Ù ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ ¾îÇÁ·ÎÄ¡
    • Åé´Ù¿î ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Á¤¸Æ³» ¿ä¹ý¡¤Á¤¸Æ ¾×¼¼½º ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

  • ÀÓº£µðµå Æ÷Æ®
  • Á¤¸Æ Ä«Å×ÅÍ
  • ÇÇÇÏ ÁÖ»çħ
  • ÁÖÀÔ ÆßÇÁ
  • ±âŸ

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ¿µ¾ç¡¤¿ÏÃæ¾×
  • º¼·ý ÀͽºÆÒ´õ
  • Åõ¾à °ü¸®
  • Ç÷¾× ±â¹Ý Á¦Ç°

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • Ŭ¸®´Ð

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦10Àå ÃËÁø¿äÀΡ¤¾ïÁ¦¿äÀΡ¤±âȸ

  • °³¿ä
  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀïÀÇ Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
    • AngioDynamics Inc.
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Becton Dickinson and Company
    • Cardinal Health Inc.
    • Fresenius SE & Co. KGaA
    • ICU Medical Inc.
    • Medtronic plc
    • Tekni-Plex Inc.
    • Teleflex Incorporated
    • Terumo Corporation
    • Vygon SAS
KSA 25.04.07

The global intravenous (IV) therapy and vein access market size reached USD 26.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 39.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033. The growing prevalence of chronic diseases, the increasing incidences of road accidents, and the rising consumer awareness about the benefits of IV therapy represent some of the key factors driving the market.

Intravenous (IV) therapy is a medical procedure that involves administering fluids, medications, and nutrition directly into the bloodstream through a vein. This technique is commonly used in hospitals, clinics, and other healthcare facilities to treat various conditions and illnesses. Vein access is the process of entering a vein in order to administer IV therapy. A healthcare professional typically uses a needle to puncture the skin and access a vein, which can be challenging in some patients due to factors such as small or damaged veins, dehydration, and obesity. There are several types of IV therapy, including saline solutions for dehydration, antibiotics for infections, and chemotherapy for cancer treatment. In addition to treating medical conditions, IV therapy can also be used for preventative measures, such as receiving vaccinations and vitamins.

Intravenous (IV) Therapy and Vein Access Market Trends:

The increasing prevalence of chronic and lifestyle diseases, such as cancer, diabetes, and autoimmune diseases that require long-term medication and monitoring, is primarily driving the global intravenous (IV) therapy and vein access market growth. Besides this, the rising incidences of road accidents and the surging number of trauma cases are contributing to the market growth. Moreover, the escalating consumer awareness about the benefits of IV therapy and vein access and the rise in critical care therapies are presenting remunerative growth opportunities for the market. In line with this, the shifting preference for minimally invasive procedures is acting as another significant growth-inducing factor. In addition to this, numerous technological advancements in the healthcare industry to reduce the needed time and effort, lower the risk of infection, and improve the accuracy of the procedure are creating a positive outlook for the market. Concurrent with this, extensive investments in research and development (R&D) activities for innovating new therapies, drugs, and devices are aiding in market expansion. Furthermore, the increasing healthcare expenditure, rise in the number of hospitals, the widespread adoption of home healthcare, and the expanding geriatric population are strengthening the market growth.

Key Market Segmentation:

Type Insights:

  • Implantable Ports
  • Intravenous Catheters
  • Hypodermic Needles
  • Infusion Pumps
  • Others

Application Insights:

  • Nutrition and Buffer Solution
  • Volume Expander
  • Medication Administration
  • Blood Based Products

End User Insights:

  • Hospitals
  • Ambulatory Surgical Center
  • Clinics

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for intravenous (IV) therapy and vein access. Some of the factors driving the North America intravenous (IV) therapy and vein access market included the growing prevalence of chronic diseases, the increasing number of road accidents, and the expanding geriatric population.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global intravenous (IV) therapy and vein access market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AngioDynamics Inc., B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Cardinal Health Inc., Fresenius SE & Co. KGaA, ICU Medical Inc., Medtronic plc, Tekni-Plex Inc., Teleflex Incorporated, Terumo Corporation, Vygon SAS, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global intravenous (IV) therapy and vein access market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global intravenous (IV) therapy and vein access market?
  • What is the impact of each driver, restraint, and opportunity on the global intravenous (IV) therapy and vein access market?
  • What are the key regional markets?
  • Which countries represent the most attractive intravenous (IV) therapy and vein access market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the intravenous (IV) therapy and vein access market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the intravenous (IV) therapy and vein access market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the intravenous (IV) therapy and vein access market?
  • What is the competitive structure of the global intravenous (IV) therapy and vein access market?
  • Who are the key players/companies in the global intravenous (IV) therapy and vein access market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Intravenous (IV) Therapy and Vein Access Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Implantable Ports
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intravenous Catheters
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hypodermic Needles
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Infusion Pumps
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Nutrition and Buffer Solution
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Volume Expander
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Medication Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Blood Based Products
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Center
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AngioDynamics Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 B. Braun Melsungen AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Baxter International Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Cardinal Health Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Fresenius SE & Co. KGaA
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICU Medical Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Tekni-Plex Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Teleflex Incorporated
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Terumo Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Vygon SAS
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦